Outcomes in Resected Melanoma Influenced by Timing of Recurrence
MedPage Today) — Early recurrence after adjuvant anti-PD-1/L1 therapy for melanoma portended shorter survival, and these patients benefited more from non-PD-1-targeted systemic therapies, a subgroup analysis of a randomized trial showed. Recurrence…
Read more